

# Christos J Markopoulos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4824144/publications.pdf>

Version: 2024-02-01

159  
papers

6,547  
citations

145106

33  
h-index

75989

78  
g-index

161  
all docs

161  
docs citations

161  
times ranked

8709  
citing authors

#	ARTICLE	IF	CITATIONS
1	Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 60-78.	1.0	5
2	Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low-Status for Breast Cancer. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 775-783.	1.2	20
3	Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial. <i>British Journal of Cancer</i> , 2022, 127, 695-703.	2.9	2
4	Clinical Utility of Functional RNA Analysis for the Reclassification of Splicing Gene Variants in Hereditary Cancer. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 285-294.	1.0	6
5	Current Concept of Sentinel Lymph Node Biopsy. , 2021, , 499-507.		0
6	Comparative survival analysis of multiparametric tests when molecular tests disagree A TEAM Pathology study. <i>Npj Breast Cancer</i> , 2021, 7, 90.	2.3	0
7	Multigene assays in early breast cancer: Insights from recent phase 3 studies. <i>European Journal of Surgical Oncology</i> , 2020, 46, 656-666.	0.5	20
8	Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3273-3281.	0.8	20
9	The challenge of avoiding over- and under-treatment in older women with ductal cancer in situ: A scoping review of existing knowledge gaps and a meta-analysis of real-world practice patterns. <i>Journal of Geriatric Oncology</i> , 2020, 11, 917-925.	0.5	1
10	Theoretical and practical knowledge curriculum for European Breast Surgeons. <i>European Journal of Surgical Oncology</i> , 2020, 46, 717-736.	0.5	12
11	Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1549-1564.	2.0	19
12	Omitting chemotherapy in more patients with early breast cancer in the post-TAILORx era.. <i>Journal of Clinical Oncology</i> , 2020, 38, e12534-e12534.	0.8	1
13	European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. <i>Breast Care</i> , 2019, 14, 359-365.	0.8	4
14	Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations. <i>BMC Cancer</i> , 2019, 19, 535.	1.1	77
15	Towards Harmonisation of Breast Care in Europe. <i>Breast Care</i> , 2019, 14, 341-343.	0.8	1
16	Abstract P4-03-07: Analysis of hereditary cancer syndromes by using a panel of genes: Novel and multiple pathogenic mutations. , 2019, , .		0
17	Educational and Training Harmonization in Breast Care. , 2019, , 64-70.		0
18	Molecular Profiling of Breast Cancer and DCIS. , 2018, , 89-101.		0

#	ARTICLE	IF	CITATIONS
19	Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 616-627.	3.0	8
20	Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center. <i>Cancer Genetics</i> , 2018, 220, 1-12.	0.2	11
21	MCQ Self-Test. , 2018, , 715-718.		0
22	Complications of Breast Surgery and Their Management. , 2018, , 411-423.		1
23	Controversies and recommendations regarding sentinel lymph node biopsy in primary breast cancer: A comprehensive review of current data. <i>European Journal of Surgical Oncology</i> , 2018, 44, 5-14.	0.5	35
24	Pathway-based subnetworks enable cross-disease biomarker discovery. <i>Nature Communications</i> , 2018, 9, 4746.	5.8	30
25	Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial. <i>PLoS ONE</i> , 2018, 13, e0200302.	1.1	21
26	Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. <i>European Journal of Cancer</i> , 2018, 99, 1-8.	1.3	38
27	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. <i>Npj Breast Cancer</i> , 2017, 3, 3.	2.3	17
28	The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2 <sup>-</sup> ) breast cancer: When might multigene assays be of value?. <i>Breast</i> , 2017, 33, 191-199.	0.9	4
29	Controversial issues in the management of older adults with early breast cancer. <i>Journal of Geriatric Oncology</i> , 2017, 8, 397-402.	0.5	9
30	Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1211-1220.	5.1	45
31	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. <i>Translational Oncology</i> , 2017, 10, 589-598.	1.7	17
32	Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?. <i>European Journal of Surgical Oncology</i> , 2017, 43, 909-920.	0.5	34
33	The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy. <i>Anticancer Research</i> , 2017, 37, 2947-2957.	0.5	9
34	Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, 524-524.	0.8	1
35	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 307-321.	1.1	16
36	Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons. <i>Breast</i> , 2016, 27, 27-34.	0.9	2

#	ARTICLE	IF	CITATIONS
37	Screening mammography: Usefulness beyond early detection of breast cancer. <i>Atherosclerosis</i> , 2016, 248, 1.	0.4	6
38	The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc99 and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 281-294.	1.1	98
39	White blood cell and platelet indices as prognostic markers in patients with invasive ductal breast carcinoma. <i>Oncology Letters</i> , 2016, 12, 1610-1614.	0.8	15
40	Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 66-74.	1.2	33
41	Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. <i>Annals of Oncology</i> , 2016, 27, 379-390.	0.6	165
42	A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer. <i>Advances in Therapy</i> , 2015, 32, 1237-1247.	1.3	32
43	Inflammatory Myofibroblastic Tumor of the Breast. <i>Case Reports in Surgery</i> , 2015, 2015, 1-5.	0.2	16
44	Surgery for liver metastases from breast cancer. <i>Future Oncology</i> , 2015, 11, 1519-1530.	1.1	13
45	Does patient education work in breast cancer? Final results from the global CARIATIDE study. <i>Future Oncology</i> , 2015, 11, 205-217.	1.1	23
46	Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. <i>Lancet, The</i> , 2015, 386, 1341-1352.	6.3	1,072
47	Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. <i>Lancet, The</i> , 2015, 386, 1353-1361.	6.3	581
48	P247 A laboratory comparison of the 21-gene assay and PAM50-ROR. <i>Breast</i> , 2015, 24, S110-S111.	0.9	1
49	Combination of Calcium Hydroxyapatite Antibiotic Carrier with Cement Spacers in Peri-Prosthetic Knee Infections. <i>Surgical Infections</i> , 2015, 16, 748-754.	0.7	5
50	Abstract P1-03-08: Different genomic rearrangements account for 17% of BRCA1/2 mutations in Greece. , 2015, , .		1
51	Abstract P4-11-10: Time dependence of biomarkers: Non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer. , 2015, , .		1
52	Abstract P4-11-09: Comparison of immunohistochemical residual risk panels to predict risk in early breast cancers treated with endocrine therapy. , 2015, , .		1
53	Abstract S2-01: Theranostic multiparametric tests improve residual risk assessment in early luminal breast cancer. , 2015, , .		1
54	Abstract P4-11-05: Does androgen receptor (AR) expression impact on residual risk? A TEAM pathology study. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract P6-08-06: The multidisciplinary application of genomics in clinical practice (MAGIC) survey: Identification of early stage hormone receptor-positive (HR+), HER2 <sup>+</sup> breast cancer (BC) patients for whom multigene assays may be valuable. , 2015, , .		0
56	Effect of mutant TP53 genotypes on the outcome of breast cancer (BC) patients in different clinical tumor subtypes.. Journal of Clinical Oncology, 2015, 33, 11041-11041.	0.8	0
57	The Effect of Physician'S Characteristics on Adjuvant Chemotherapy (Ct) Decisions for Early Stage Hr + , Her2 <sup>+</sup> Breast Cancer (Bc) Patients (Pts). Annals of Oncology, 2014, 25, iv88.	0.6	0
58	The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes. Anti-Cancer Drugs, 2014, 25, 950-957.	0.7	32
59	Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study. Journal of Clinical Oncology, 2014, 32, 2951-2958.	0.8	101
60	The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First-year results from the Compliance of ARomatase Inhibitors Assessment In Daily practice through Educational approach (CARIATIDE) study. Breast, 2014, 23, 393-399.	0.9	44
61	When and how to operate on thoracic and lumbar spine fractures?. European Journal of Orthopaedic Surgery and Traumatology, 2014, 24, 443-451.	0.6	10
62	Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer. British Journal of Cancer, 2014, 111, 2242-2247.	2.9	14
63	157. Comparing medical oncologists' and surgeons' treatment recommendations in early stage HR+, HER2 <sup>+</sup> breast cancer (BC) patients (pts): A subanalysis of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey. European Journal of Surgical Oncology, 2014, 40, S69.	0.5	0
64	Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer, 2014, 14, 515.	1.1	26
65	A New Mathematical Model for the Interpretation of Translational Research Evaluating Six CTLA-4 Polymorphisms in High-Risk Melanoma Patients Receiving Adjuvant Interferon. PLoS ONE, 2014, 9, e86375.	1.1	3
66	Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen. World Journal of Clinical Oncology, 2014, 5, 374.	0.9	6
67	A pilot laboratory study comparing the 21-gene assay and PAM50-ROR.. Journal of Clinical Oncology, 2014, 32, 11003-11003.	0.8	0
68	Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis. Journal of Clinical Oncology, 2013, 31, 2257-2264.	0.8	64
69	Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?. Breast, 2013, 22, 488-494.	0.9	3
70	Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Radiotherapy and Oncology, 2013, 108, 190-196.	0.3	25
71	Breast cancer in the elderly: reducing the losses. Future Oncology, 2013, 9, 1253-1256.	1.1	3
72	Elderly Postmenopausal Patients With Breast Cancer Are at Increased Risk for Distant Recurrence: A Tamoxifen Exemestane Adjuvant Multinational Study Analysis. Oncologist, 2013, 18, 8-13.	1.9	21

#	ARTICLE	IF	CITATIONS
73	Overview of the use of OncotypeDX® as an additional treatment decision tool in early breast cancer. Expert Review of Anticancer Therapy, 2013, 13, 179-194.	1.1	31
74	Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. British Journal of Cancer, 2013, 109, 2453-2461.	2.9	6
75	Conference Scene: Breast cancer management: towards optimum diagnostic and therapeutic methods. Breast Cancer Management, 2013, 2, 459-462.	0.2	0
76	Older patients with breast cancer: is there bias in the treatment they receive?. Therapeutic Advances in Medical Oncology, 2012, 4, 321-327.	1.4	33
77	Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study. Journal of Clinical Oncology, 2012, 30, 4477-4484.	0.8	58
78	Are we treating the elderly with breast cancer to the same standard as younger patients?. Aging Health, 2012, 8, 1-3.	0.3	1
79	Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor-Positive Breast Cancer. Obstetrical and Gynecological Survey, 2012, 67, 415-416.	0.2	0
80	Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1569-1577.	1.2	5
81	Clinical experience of using oncotype DX as an additional treatment decision tool in early breast cancer – A retrospective analysis from 5 Greek institutions. European Journal of Surgical Oncology, 2012, 38, 413-419.	0.5	11
82	Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor-Positive Breast Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 590-7.	3.8	182
83	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Research and Treatment, 2012, 132, 609-619.	1.1	48
84	Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches.. Journal of Clinical Oncology, 2012, 30, 517-517.	0.8	5
85	Computer-Assisted Navigation in Knee Surgery. Journal of Long-Term Effects of Medical Implants, 2012, 22, 313-322.	0.2	2
86	The role of Ki-67 in molecular breast cancer classification.. Journal of Clinical Oncology, 2012, 30, 583-583.	0.8	1
87	Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the TEAM pathology study.. Journal of Clinical Oncology, 2012, 30, 516-516.	0.8	0
88	Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology, 2011, 29, 1531-1538.	0.8	160
89	Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet, The, 2011, 377, 321-331.	6.3	346
90	P343 CARIATIDE trial: the impact of educational materials (EM) on patients' compliance with adjuvant aromatase inhibitor (AI) therapy and quality of life (QoL). Breast, 2011, 20, S83-S84.	0.9	0

#	ARTICLE	IF	CITATIONS
91	Heterogeneous HER2 Gene Amplification. American Journal of Clinical Pathology, 2011, 136, 266-274.	0.4	101
92	P5-16-02: The Impact of Educational Materials on Compliance and Persistence with Adjuvant Aromatase Inhibitors: 2 Year Follow-Up and Final Results from the CARIATIDE Study.. , 2011, , .		2
93	Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials. Cancer and Metastasis Reviews, 2010, 29, 581-594.	2.7	13
94	Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer, 2010, 116, 4326-4333.	2.0	35
95	Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. British Journal of Surgery, 2010, 97, 671-679.	0.1	28
96	Effect of aromatase inhibitors on the lipid profile of postmenopausal breast cancer patients. Clinical Lipidology, 2010, 5, 245-254.	0.4	4
97	Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. Journal of Translational Medicine, 2010, 8, 108.	1.8	25
98	Phantom breast syndrome: The effect of in situ breast carcinoma. Psychiatry Research, 2010, 179, 333-337.	1.7	7
99	Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important. Breast Cancer Research, 2010, 12, 403.	2.2	2
100	Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Research, 2010, 12, R24.	2.2	70
101	Abstract P1-10-03: CARIATIDE: The Impact of Educational Materials and Demographic Characteristics on Compliance with Adjuvant Aromatase Inhibitor Treatment. , 2010, , .		0
102	Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Annals of Oncology, 2009, 20, 49-55.	0.6	39
103	Impact of Breast Cancer Surgery on the Self-Esteem and Sexual Life of Female Patients. Journal of International Medical Research, 2009, 37, 182-188.	0.4	124
104	Aromatase inhibitors in the management of early breast cancer: The TEAM trial. European Journal of Surgical Oncology, 2009, 35, 333.	0.5	2
105	Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Research, 2009, 11, R35.	2.2	31
106	Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients. Breast Cancer Research and Treatment, 2008, 107, 431-441.	1.1	38
107	Depressive symptomatology correlates with phantom breast syndrome in mastectomized women. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 165-170.	1.8	16
108	Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor. Surgical Oncology, 2008, 17, 113-128.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Glycogen-rich clear cell carcinoma of the breast. <i>World Journal of Surgical Oncology</i> , 2008, 6, 44.	0.8	26
110	Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. <i>Annals of Oncology</i> , 2008, 19, 853-860.	0.6	45
111	Mitoxantrone Plus Vinorelbine in Pretreated Patients with Metastatic Breast Cancer. <i>Journal of Chemotherapy</i> , 2007, 19, 582-589.	0.7	13
112	Mitoxantrone Plus Gemcitabine in Pretreated Patients with Metastatic Breast Cancer. <i>Journal of Chemotherapy</i> , 2006, 18, 192-198.	0.7	4
113	Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2006, 96, 251-261.	1.1	42
114	Paraffinomas of the breast or oleogranulomatous mastitis—a rare entity. <i>Breast</i> , 2006, 15, 540-543.	0.9	10
115	Duration of Tamoxifen Effect on Lipidemic Profile of Postmenopausal Breast Cancer Patients following Deprivation of Treatment. <i>Oncology</i> , 2006, 70, 301-305.	0.9	11
116	Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2006, 17, 1835-1841.	0.6	23
117	Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon. <i>New England Journal of Medicine</i> , 2006, 354, 709-718.	13.9	593
118	Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. <i>Anti-Cancer Drugs</i> , 2005, 16, 879-883.	0.7	30
119	Development of Early Malignant Bilateral Breast Disease in Relation to Antidepressant Treatment. <i>Acta Chirurgica Belgica</i> , 2005, 105, 660-661.	0.2	2
120	Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals - correlation with clinicopathological data. <i>Clinical Genetics</i> , 2005, 67, 322-329.	1.0	9
121	Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. <i>Breast Cancer Research and Treatment</i> , 2005, 92, 1-9.	1.1	35
122	The Effect of Exemestane on the Lipidemic Profile of Postmenopausal Early Breast Cancer Patients: Preliminary Results of the TEAM Greek Sub-study. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 61-66.	1.1	63
123	Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2005, 16, 1762-1771.	0.6	95
124	Should women be advised to take prophylactic endocrine treatment outside of a clinical trial setting?. <i>Annals of Oncology</i> , 2005, 16, 1861-1866.	0.6	4
125	Adiponectin and Breast Cancer Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1102-1107.	1.8	488
126	Breast arterial calcifications as an indicator of systemic vascular disease. <i>Acta Radiologica</i> , 2004, 45, 726-729.	0.5	17



#	ARTICLE	IF	CITATIONS
127	Metastatic Melanoma in the Gallbladder: Report of a Case. <i>Surgery Today</i> , 2003, 33, 135-137.	0.7	25
128	Immunohistochemical evaluation of immune response in invasive ductal breast cancer of not-otherwise-specified type. <i>Breast</i> , 2003, 12, 172-178.	0.9	34
129	Adenosis Tumor of the Breast. <i>Breast Journal</i> , 2003, 9, 255-256.	0.4	8
130	Full Dose Paclitaxel Plus Vinorelbine as Salvage Chemotherapy in Anthracycline-Resistant Advanced Breast Cancer: A Phase II Study. <i>Journal of Chemotherapy</i> , 2003, 15, 607-612.	0.7	19
131	Pre-operative Tc-99m-Sestamibi Scanning and Intra-Operative Nuclear Mapping: Are they Accurate In Localizing Parathyroid Adenomas ?. <i>Acta Chirurgica Belgica</i> , 2003, 103, 626-630.	0.2	5
132	Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer. <i>Anticancer Research</i> , 2003, 23, 2917-23.	0.5	7
133	Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx®) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2002, 13, 1737-1742.	0.6	59
134	BRCA2 gene mutations in Greek patients with familial breast cancer. <i>Human Mutation</i> , 2002, 19, 81-82.	1.1	35
135	High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas. <i>Cancer</i> , 2002, 94, 2454-2465.	2.0	37
136	High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas. , 2002, 94, 2454.		1
137	Diagnosis and treatment of intracystic breast carcinomas. <i>American Surgeon</i> , 2002, 68, 783-6.	0.4	11
138	Autoimmune thyroid disease in women with breast carcinoma. <i>European Journal of Surgical Oncology</i> , 2001, 27, 626-630.	0.5	27
139	Use of artificial neural networks (computer analysis) in the diagnosis of microcalcifications on mammography. <i>European Journal of Radiology</i> , 2001, 39, 60-65.	1.2	29
140	p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas. <i>Cytopathology</i> , 2001, 12, 197-202.	0.4	12
141	Breast Cancer in Older Women. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 1004-1005.	1.3	0
142	Primary Actinomycosis Of The Greater Omentum. <i>Journal of Infection</i> , 2001, 43, 159-160.	1.7	6
143	Metastatic Retroperitoneal and Mediastinal Fibrosis as First Sign of Recurrence of Breast Cancer. <i>The European Journal of Surgery</i> , 2001, 167, 715-718.	1.0	10
144	Leptin and insulin growth factor I in relation to breast cancer (Greece). <i>Cancer Causes and Control</i> , 2000, 11, 383-388.	0.8	115

#	ARTICLE	IF	CITATIONS
145	Doxorubicin plus Ifosfamide as Salvage Treatment for Patients with Advanced Breast Cancer Refractory to Epirubicin plus Cyclophosphamide. <i>Clinical Drug Investigation</i> , 2000, 19, 349-355.	1.1	1
146	Management of Nonpalpable, Mammographically Detectable Breast Lesions. <i>World Journal of Surgery</i> , 1999, 23, 434-438.	0.8	17
147	Changes of Chromosomes 1, 3, 6, and 11 in Metastatic Effusions Arising from Breast and Ovarian Cancer. <i>Cancer Genetics and Cytogenetics</i> , 1999, 110, 34-40.	1.0	12
148	p53 Protein Expression in Benign and Malignant Breast Lesions. <i>Acta Cytologica</i> , 1998, 42, 918-922.	0.7	4
149	Sex Hormones in Postmenopausal Women with Breast Cancer on Tamoxifen. <i>Hormone Research</i> , 1997, 47, 116-120.	1.8	27
150	Expression of pS2 Protein and Estrogen and Progesterone Receptor Status in Breast Cancer. <i>Acta Cytologica</i> , 1997, 41, 713-716.	0.7	7
151	DNA content and p53 protein expression in ductal breast cancer. <i>Cytopathology</i> , 1997, 8, 322-327.	0.4	4
152	Application of back propagation to the diagnosis of breast lesions by fine needle aspiration. <i>Breast</i> , 1997, 6, 293-298.	0.9	17
153	DNA ploidy and pS2 protein expression in breast cancer. <i>Cytopathology</i> , 1997, 8, 171-176.	0.4	7
154	Fournier's gangrene: still highly lethal. <i>Langenbecks Archiv Fur Chirurgie</i> , 1997, 382, 15-18.	0.2	2
155	DNA ploidy and vimentin expression in primary breast cancer. <i>Cytopathology</i> , 1995, 6, 325-330.	0.4	1
156	Bone mineral density in postmenopausal women with breast cancer and the effect of tamoxifen. <i>Breast</i> , 1994, 3, 14-19.	0.9	0
157	Expression of alpha-thymosins in human tissues in normal and abnormal growth.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 9504-9507.	3.3	71
158	TAMOXIFEN AND BREAST CANCER IN THE ELDERLY. <i>Lancet, The</i> , 1988, 331, 1218.	6.3	0
159	Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. <i>BMJ: British Medical Journal</i> , 1988, 296, 1349-1351.	2.4	95